{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ulcerative-colitis/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"12402ddb-2eb9-589e-a1c3-24d50e2538f8","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 585573c4-6526-40c8-ad5c-4fea0c1cc563 --><h2>Update</h2><!-- end field 585573c4-6526-40c8-ad5c-4fea0c1cc563 -->","summary":null,"htmlStringContent":"<!-- begin item 9ccb2185-3ddc-4296-b13e-dc52f5f52867 --><!-- end item 9ccb2185-3ddc-4296-b13e-dc52f5f52867 -->","topic":{"id":"34aee656-b482-5065-8656-44c487e4e347","topicId":"6a63bd87-53c1-487d-8426-773cffdb4c43","topicName":"Ulcerative colitis","slug":"ulcerative-colitis","lastRevised":"Last revised in April 2020","chapters":[{"id":"8ec19c69-a796-514b-a267-91bd57a12fe3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dc4de3c1-9955-536e-9789-a900261d2189","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"04875f8c-29b3-5d60-8e5c-06930138cfc4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04f00df3-2de5-5c61-bb95-25edda5f885b","slug":"changes","fullItemName":"Changes"},{"id":"12402ddb-2eb9-589e-a1c3-24d50e2538f8","slug":"update","fullItemName":"Update"}]},{"id":"2c186889-f3c1-5094-b0ce-0b9a81f46d61","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"36a3da73-b00f-5ee2-bfd9-33293a674904","slug":"goals","fullItemName":"Goals"},{"id":"5c86e0bc-3476-59dd-b120-519602968645","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3ab8e65e-aac9-54a1-abb3-9185c76c6004","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0efa89a1-51f7-59ff-95ce-94faac48f8a5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a2b17331-6cfc-56eb-84c5-433f78f4364c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"01a70081-193a-5d75-92fb-45f84ee7b317","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"87cfff6e-6028-5fda-aee6-4473268cac77","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"116a07eb-6832-5d49-aa1d-497f7c0684a9","slug":"definition","fullItemName":"Definition"},{"id":"fef2143b-1809-58f3-bdf9-0d73710d89ae","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9c9a2e21-7e98-5876-945d-ec18ebfaee62","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5102ad12-cd60-5939-ad9a-00d4dafca9b0","slug":"complications","fullItemName":"Complications"},{"id":"488ac85b-91d2-5298-9127-69ae212ceeac","slug":"extra-intestinal-manifestations","fullItemName":"Extra-intestinal manifestations"},{"id":"9ff94ba6-78d6-5ed0-9cda-f234b24236d7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2149059a-c90f-50e5-9fa2-227a488d2004","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"40b81845-1ebc-55b2-b825-05a3d62e3cc4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"0102b680-c790-5c87-aaec-ea332f5fc9b2","slug":"investigations","fullItemName":"Investigations"},{"id":"2ea841c6-272f-5b4b-a165-499ec0228439","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"468c6dcc-e9f2-5154-9f2b-30d7dafb7415","fullItemName":"Management","slug":"management","subChapters":[{"id":"6a9b8b90-a418-5e1b-9442-ac55ee36430f","slug":"suspected-ulcerative-colitis","fullItemName":"Scenario: Suspected ulcerative colitis"},{"id":"6d8002d3-29fe-5bfd-ba03-7ce0173636e4","slug":"confirmed-ulcerative-colitis","fullItemName":"Scenario: Confirmed ulcerative colitis"},{"id":"56868b16-5233-5bb8-9412-d2d9bfafe8d9","slug":"fertility-pregnancy-breastfeeding-with-ulcerative-colitis","fullItemName":"Scenario: Fertility, pregnancy, and breastfeeding with ulcerative colitis"},{"id":"7708c2de-0c02-5b83-a354-70788b3dc297","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"010b277d-6575-5cdc-b995-6fc7d89fb745","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a8ed7157-985a-58a5-b567-571fa748a73b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a1164542-c6ec-5b63-bfee-efc59657c778","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"568370d3-2e5b-55a4-ae50-2eeeb5ca3234","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"df1aecf8-eeb0-5069-965e-21ccf0690af8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"889198a1-b809-54b2-b803-3ee02e6f45af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a290d39a-e351-5dec-9607-943a59e60b2e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"916d81a4-ae1e-529e-936f-183b4514ba9f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"04875f8c-29b3-5d60-8e5c-06930138cfc4","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"d530e5b7-057f-51c0-8782-8acf7a3c309a","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 5011ffaf-1899-415e-8bb0-c43323e8e7f7 --><h3>New evidence</h3><!-- end field 5011ffaf-1899-415e-8bb0-c43323e8e7f7 -->","summary":null,"htmlStringContent":"<!-- begin item 68b0079f-481d-4999-b2b5-ebc056dc8136 --><!-- begin field fc7a895f-17ee-4057-8754-93f1c02fd7ce --><h3>Evidence-based guidelines</h3><!-- end field fc7a895f-17ee-4057-8754-93f1c02fd7ce --><!-- begin field dc0f2694-5d95-49e0-9174-d7a0ebd3ea92 --><ul><li>BSG (2019) <em>BSG consensus guidelines on the management of inflammatory bowel disease in adults. British Society of Gastroenterology. </em><a href=\"https://www.bsg.org.uk/\" data-hyperlink-id=\"683f6924-aa5c-4da1-82f8-aa8100d1e0e7\">www.bsg.org.uk</a> [<a href=\"https://www.bsg.org.uk/resource/bsg-consensus-guidelines-ibd-in-adults.html\" data-hyperlink-id=\"a71bdc43-91d4-476a-a6ee-aa8100d1e13c\">Free Full-text</a>] </li></ul><!-- end field dc0f2694-5d95-49e0-9174-d7a0ebd3ea92 --><!-- begin field 8cdbe008-eb7b-4093-8bcb-ef3ed9d09080 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 8cdbe008-eb7b-4093-8bcb-ef3ed9d09080 --><!-- begin field 0ed0ef1b-4ffc-48f0-9296-f83a84029190 --><p>No new HTAs since1 March 2019.</p><!-- end field 0ed0ef1b-4ffc-48f0-9296-f83a84029190 --><!-- begin field 648cc58c-acb7-42fd-9283-ea0553c0f3bc --><h3>Economic appraisals</h3><!-- end field 648cc58c-acb7-42fd-9283-ea0553c0f3bc --><!-- begin field 1b90fbdd-ca77-4ced-ba47-4af7d5c4eda7 --><p>No new economic appraisals relevant to England since 1 March 2019.</p><!-- end field 1b90fbdd-ca77-4ced-ba47-4af7d5c4eda7 --><!-- begin field bd26672a-8220-4a71-9b46-332bf32bc9cd --><h3>Systematic reviews and meta-analyses</h3><!-- end field bd26672a-8220-4a71-9b46-332bf32bc9cd --><!-- begin field 006d2466-3b98-4edb-919b-f560e66bbe23 --><ul><li>Murray, A., Nguyen, T.M., Parker, C.E., et al. (2020) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Library. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"65d27f86-3e73-4846-87d3-ac4f00a43c63\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000544.pub5/full\" data-hyperlink-id=\"5d29d834-396e-46f0-b699-ac4f00a43d33\">Free Full-text</a>]</li></ul><!-- end field 006d2466-3b98-4edb-919b-f560e66bbe23 --><!-- begin field 79d94850-f930-40e4-bb10-3bbb3809cc0f --><h3>Primary evidence</h3><!-- end field 79d94850-f930-40e4-bb10-3bbb3809cc0f --><!-- begin field 5099ea12-3103-4100-992c-e97d05178024 --><p>No new randomized controlled trials published in the major journals since 1 March 2019.</p><!-- end field 5099ea12-3103-4100-992c-e97d05178024 --><!-- end item 68b0079f-481d-4999-b2b5-ebc056dc8136 -->","subChapters":[]},{"id":"82bd00ff-1b3a-5fd9-b412-ac9b7be37d3f","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field fdb57a54-39ce-4f1b-b911-8291f3275193 --><h3>New policies</h3><!-- end field fdb57a54-39ce-4f1b-b911-8291f3275193 -->","summary":null,"htmlStringContent":"<!-- begin item 925ebcf1-922d-48c4-9e27-c30f91f1e4c2 --><!-- begin field 6ddc8280-2760-404a-943e-1a9919497769 --><p>No new national policies or guidelines since 1 March 2019.</p><!-- end field 6ddc8280-2760-404a-943e-1a9919497769 --><!-- end item 925ebcf1-922d-48c4-9e27-c30f91f1e4c2 -->","subChapters":[]},{"id":"52513c54-215f-5478-974f-17f3b25f42a1","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 40e1a397-b101-4726-9514-5f15270487f7 --><h3>New safety alerts</h3><!-- end field 40e1a397-b101-4726-9514-5f15270487f7 -->","summary":null,"htmlStringContent":"<!-- begin item 9e7d9dbc-ab29-49c2-8601-def909da5008 --><!-- begin field 0d21d0ca-9209-4963-8677-2d320de26c4a --><p>No new safety alerts since 1 March 2019.</p><!-- end field 0d21d0ca-9209-4963-8677-2d320de26c4a --><!-- end item 9e7d9dbc-ab29-49c2-8601-def909da5008 -->","subChapters":[]},{"id":"8f4071b7-241a-5baf-8ce6-9d938cccf10d","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field d904bd6d-c9e3-4033-aec8-4f7caff00e8d --><h3>Changes in product availability</h3><!-- end field d904bd6d-c9e3-4033-aec8-4f7caff00e8d -->","summary":null,"htmlStringContent":"<!-- begin item 7a8f0845-5ef9-4e24-b31e-04a15fe2cc4d --><!-- begin field c742a127-8d2d-4892-8b4f-6ca37a099685 --><ul><li>Stelara (ustekinumab) is now indicated for the treatment of adult patients with moderately to severely active ulcerative colitis. See more <a href=\"https://www.medicines.org.uk/emc/product/4412/smpc\" data-hyperlink-id=\"df3e2658-332e-4eb0-b15d-aacd008f1bd9\">here</a>. </li><li>Octasa (mesalazine) 1600 mg modified release tablets - this new strength of Octasa tablets are licensed for the treatment of mild to moderate acute disease, and for the maintenance of remission. See more <a href=\"https://www.medicines.org.uk/emc/product/10803/smpc\" data-hyperlink-id=\"1c0c36d5-eff5-4522-9379-aae3008bdd01\">here</a>.</li><li>Zintasa is licensed to treat mild to moderate ulcerative colitis and maintain ulcerative colitis in remission. See more <a href=\"https://www.medicines.org.uk/emc/product/10953/smpc\" data-hyperlink-id=\"122e3ca3-3da5-4ddc-9295-ab5000e56e32\">here</a>.</li><li>Ustekinumab is recommended for moderately to severely active ulcerative colitis in adults when conventional therapy or a biologic cannot be tolerated, or the disease has responded inadequately or lost response only if anti-TNF has failed, is not tolerated, or not suitable. See more <a href=\"https://www.nice.org.uk/guidance/ta633\" data-hyperlink-id=\"1e0575a7-b63f-403a-adb3-abdf00a26257\">here</a>. </li></ul><!-- end field c742a127-8d2d-4892-8b4f-6ca37a099685 --><!-- end item 7a8f0845-5ef9-4e24-b31e-04a15fe2cc4d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}